ARTICLE | Product Development
Genentech positions bispecifics as durable options via ASH data
Fixed-duration doses of Lunsumio, Columvi led to responses that persisted long after treatment was stopped
December 19, 2023 9:29 PM UTC
With long-term data from a pair of approved bispecific antibodies and a pipeline strategy that incorporates new bispecific technologies and combinations, Genentech is helping change perceptions of the modality.
Once considered more accessible and somewhat safer, but less effective and durable than CAR T cell therapies, bispecifics are now proving capable of inducing long-term remission in advanced cancers. ...